Wonku Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wonku Kang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Eunyoung Kim
Graduate School for Pharmaceutical Industry Management, College of Pharmacy, Chung-Ang University, Seoul, Korea
5 shared publications Keumhan Noh
College of Pharmacy, Yeungnam University, Kyoungbuk, South Korea
5 shared publicationsEunyoung Kim
College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea
3 shared publicationsKyeumhan Noh
College of Pharmacy Yeungnam University Kyungsan Republic of Korea
3 shared publicationsByoungki Ahn
College of Pharmacy Yeungnam University Kyoungbuk South Korea
2 shared publications- Hye Sun Gwak
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University
2 shared publications
Latest Publications
- Open Access
- 31 March 2018
- Published by The Korean College of Clinical Pharmacy in Korean Journal of Clinical Pharmacy
- Vol. 28 (1) , 24-29
Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Pediatric Patients
- 31 March 2018
- Published by The Korean College of Clinical Pharmacy in Korean Journal of Clinical Pharmacy
- Vol. 28 (1) , 24-29
Open AccessPopulation Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Pediatric Patients
- Open Access
- 4 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e60556
Pharmacometabolomic Approach to Predict QT Prolongation in Guinea Pigs
Drug-induced torsades de pointes (TdP), a life-threatening arrhythmia associated with prolongation of the QT interval, has been a significant reason for withdrawal of several medicines from the market. Prolongation of the QT interval is considered as the best biomarker for predicting the torsadogenic risk of a new chemical entity. Because of the difficulty assessing the risk for TdP during drug development, we evaluated the metabolic phenotype for predicting QT prolongation induced by sparfloxacin, and elucidated the metabolic pathway related to the QT prolongation. We performed electrocardiography analysis and liquid chromatography–mass spectroscopy-based metabolic profiling of plasma samples obtained from 15 guinea pigs after administration of sparfloxacin at doses of 33.3, 100, and 300 mg/kg. Principal component analysis and partial least squares modelling were conducted to select the metabolites that substantially contributed to the prediction of QT prolongation. QTc increased significantly with increasing dose (r = 0.93). From the PLS analysis, the key metabolites that showed the highest variable importance in the projection values (>1.5) were selected, identified, and used to determine the metabolic network. In particular, cytidine-5′-diphosphate (CDP), deoxycorticosterone, L-aspartic acid and stearic acid were found to be final metabolomic phenotypes for the prediction of QT prolongation. Metabolomic phenotypes for predicting drug-induced QT prolongation of sparfloxacin were developed and can be applied to cardiac toxicity screening of other drugs. In addition, this integrative pharmacometabolomic approach would serve as a good tool for predicting pharmacodynamic or toxicological effects caused by changes in dose.
- 4 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e60556
Open AccessPharmacometabolomic Approach to Predict QT Prolongation in Guinea Pigs
Drug-induced torsades de pointes (TdP), a life-threatening arrhythmia associated with prolongation of the QT interval, has been a significant reason for withdrawal of several medicines from the market. Prolongation of the QT interval is considered as the best biomarker for predicting the torsadogenic risk of a new chemical entity. Because of the difficulty assessing the risk for TdP during drug development, we evaluated the metabolic phenotype for predicting QT prolongation induced by sparfloxacin, and elucidated the metabolic pathway related to the QT prolongation. We performed electrocardiography analysis and liquid chromatography–mass spectroscopy-based metabolic profiling of plasma samples obtained from 15 guinea pigs after administration of sparfloxacin at doses of 33.3, 100, and 300 mg/kg. Principal component analysis and partial least squares modelling were conducted to select the metabolites that substantially contributed to the prediction of QT prolongation. QTc increased significantly with increasing dose (r = 0.93). From the PLS analysis, the key metabolites that showed the highest variable importance in the projection values (>1.5) were selected, identified, and used to determine the metabolic network. In particular, cytidine-5′-diphosphate (CDP), deoxycorticosterone, L-aspartic acid and stearic acid were found to be final metabolomic phenotypes for the prediction of QT prolongation. Metabolomic phenotypes for predicting drug-induced QT prolongation of sparfloxacin were developed and can be applied to cardiac toxicity screening of other drugs. In addition, this integrative pharmacometabolomic approach would serve as a good tool for predicting pharmacodynamic or toxicological effects caused by changes in dose.
- Open Access
- 31 March 2013
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 21 (2) , 170-172
Pharmacokinetics of Uridine Following Ocular, Oral and Intravenous Administration in Rabbits
Pharmacokinetics of Uridine Following Ocular, Oral and Intravenous Administration in Rabbits Uridine;Pharmacokinetics;Topical ocular;Bioavailability;Rabbit; The pyrimidine nucleoside uridine has recently been reported to have a protective effect on cultured human corneal epithelial cells, in an animal model of dry eye and in patients. In this study, we investigate the pharmacokinetic profile of uridine in rabbits, following topical ocular (8 mg/eye), oral (450 mg/kg) and intravenous (100 mg/kg) administration. Blood and urine samples were serially taken, and uridine was measured by high-performance liquid chromatography-tandem mass spectrometry. No symptoms were noted in the animals after uridine treatment. Uridine was not detected in either plasma or urine after topical ocular administration, indicating no systemic exposure to uridine with this treatment route. Following a single intravenous dose, the plasma concentration of uridine showed a bi-exponential decay, with a rapid decline over 10 min, followed by a slow decay with a terminal half-life of $0.36{\pm}0.05$ h. Clearance and volume of distribution were $1.8{\pm}0.6$ L/h/kg and $0.58{\pm}0.32$ L/kg, respectively. The area under the plasma concentration-time curves (AUC) was $59.7{\pm}18.2{\mu}g{\cdot}hr/ml$, and urinary excretion up to 12 hr was ~7.7% of the dose. Plasma uridine reached a peak of $25.8{\pm}4.1{\mu}g/ml$ at $2.3{\pm}0.8$ hr after oral administration. The AUC was $79.0{\pm}13.9{\mu}g{\cdot}hr/ml$, representing ~29.4% of absolute bioavailability. About 1% of the oral dose was excreted in the urine. These results should prove useful in the design of future clinical and nonclinical studies conducted with uridine.- 31 March 2013
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 21 (2) , 170-172
Open AccessPharmacokinetics of Uridine Following Ocular, Oral and Intravenous Administration in Rabbits
Pharmacokinetics of Uridine Following Ocular, Oral and Intravenous Administration in Rabbits Uridine;Pharmacokinetics;Topical ocular;Bioavailability;Rabbit; The pyrimidine nucleoside uridine has recently been reported to have a protective effect on cultured human corneal epithelial cells, in an animal model of dry eye and in patients. In this study, we investigate the pharmacokinetic profile of uridine in rabbits, following topical ocular (8 mg/eye), oral (450 mg/kg) and intravenous (100 mg/kg) administration. Blood and urine samples were serially taken, and uridine was measured by high-performance liquid chromatography-tandem mass spectrometry. No symptoms were noted in the animals after uridine treatment. Uridine was not detected in either plasma or urine after topical ocular administration, indicating no systemic exposure to uridine with this treatment route. Following a single intravenous dose, the plasma concentration of uridine showed a bi-exponential decay, with a rapid decline over 10 min, followed by a slow decay with a terminal half-life of $0.36{\pm}0.05$ h. Clearance and volume of distribution were $1.8{\pm}0.6$ L/h/kg and $0.58{\pm}0.32$ L/kg, respectively. The area under the plasma concentration-time curves (AUC) was $59.7{\pm}18.2{\mu}g{\cdot}hr/ml$, and urinary excretion up to 12 hr was ~7.7% of the dose. Plasma uridine reached a peak of $25.8{\pm}4.1{\mu}g/ml$ at $2.3{\pm}0.8$ hr after oral administration. The AUC was $79.0{\pm}13.9{\mu}g{\cdot}hr/ml$, representing ~29.4% of absolute bioavailability. About 1% of the oral dose was excreted in the urine. These results should prove useful in the design of future clinical and nonclinical studies conducted with uridine. - Open Access
- 13 March 2013
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (3) , 196-202
An evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications
What is known and Objective Prescribing sulfonamide‐containing medications for patients with sulfonamide allergy continues to complicate medical decisions. We examined the cautionary recommendations in the approved drug monographs and primary literature, and formulated an evidence‐based grading of cautionary recommendations for sulfonamide allergy and cross‐reactivity among sulfonamide‐containing medications. Methods Drug monographs were collected from six countries and three drug compendia. Two reviewers independently extracted the data from the contraindication, warning and/or precaution sections of drug monographs. Evidence for cross‐reactivity was examined in the primary literature and compared with drug monograph recommendations. Consequently, medications were categorized based on the strength of recommendation and level of evidence by consensus. Results and Discussion We identified wide variability in cautionary recommendations ranging from no warning or precaution to contraindication among the sources reviewed. The recommendations were located mainly in the contraindication section of monographs for France (65·2%), United Kingdom (51·9%), Italy (50·0%), South Korea (43·5%), United States (38·2%) and Canada (37·0%), whereas in drug compendia, the recommendations were found in the precaution section for Martindale (51·4%) and Micromedex‐Drugdex (33·3%), and contraindication and precaution section for the American Hospital Formulary Service Drug Information 2010 (30·8%). Evidence from the primary literature varied with recommendation included in drug monographs. Evidence‐based categorization was carried out for 16 medications. Two sulfonamide‐moiety‐containing drugs were considered safe, six non‐sulfonylarylamines required precaution, and eight medications from all three sulfonamide chemical classes were considered mostly unsafe. What is new and Conclusion There are significant discrepancies in cautionary recommendations included in drug‐labels and drug compendia. Statements concerning cross‐reactive hypersensitivity with other sulfonamides generally suggest theoretical possibilities. The consensus evidence‐based grading instrument developed may be useful for deriving cautionary recommendations for sulfonamide‐allergic patients.
- 13 March 2013
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (3) , 196-202
Open AccessAn evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications
What is known and Objective Prescribing sulfonamide‐containing medications for patients with sulfonamide allergy continues to complicate medical decisions. We examined the cautionary recommendations in the approved drug monographs and primary literature, and formulated an evidence‐based grading of cautionary recommendations for sulfonamide allergy and cross‐reactivity among sulfonamide‐containing medications. Methods Drug monographs were collected from six countries and three drug compendia. Two reviewers independently extracted the data from the contraindication, warning and/or precaution sections of drug monographs. Evidence for cross‐reactivity was examined in the primary literature and compared with drug monograph recommendations. Consequently, medications were categorized based on the strength of recommendation and level of evidence by consensus. Results and Discussion We identified wide variability in cautionary recommendations ranging from no warning or precaution to contraindication among the sources reviewed. The recommendations were located mainly in the contraindication section of monographs for France (65·2%), United Kingdom (51·9%), Italy (50·0%), South Korea (43·5%), United States (38·2%) and Canada (37·0%), whereas in drug compendia, the recommendations were found in the precaution section for Martindale (51·4%) and Micromedex‐Drugdex (33·3%), and contraindication and precaution section for the American Hospital Formulary Service Drug Information 2010 (30·8%). Evidence from the primary literature varied with recommendation included in drug monographs. Evidence‐based categorization was carried out for 16 medications. Two sulfonamide‐moiety‐containing drugs were considered safe, six non‐sulfonylarylamines required precaution, and eight medications from all three sulfonamide chemical classes were considered mostly unsafe. What is new and Conclusion There are significant discrepancies in cautionary recommendations included in drug‐labels and drug compendia. Statements concerning cross‐reactive hypersensitivity with other sulfonamides generally suggest theoretical possibilities. The consensus evidence‐based grading instrument developed may be useful for deriving cautionary recommendations for sulfonamide‐allergic patients.
- 17 July 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (17) , 2219-2222
Quantitative determination of aceclofenac and its three major metabolites in rat plasma by HPLC‐MS/MS
We developed a method for the simultaneous quantification of aceclofenac and its three major metabolites in rat plasma. After protein precipitation with acetonitrile including flufenamic acid as an internal standard (IS), aceclofenac, diclofenac, 4′‐hydroxyaceclofenac, 4′‐hydroxydiclofenac, and the IS were chromatographed on a reverse‐phase C18 analytical column. The isocratic mobile phase of acetonitrile/0.1% formic acid (aq; 9:1 [v/v]) was eluted at 0.3 mL/min. Quantification was performed on a triple‐quadrupole mass spectrometer using electrospray ionization, and the ion transitions were monitored in selective reaction‐monitoring mode. The coefficient of variation in the assay precision was less than 8%, and the accuracy was 92–103%. This method was successfully used to measure the concentrations of aceclofenac and its three major metabolites in rat plasma following the oral administration of a single 20 mg/kg oral dose of aceclofenac.
- 17 July 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (17) , 2219-2222
Quantitative determination of aceclofenac and its three major metabolites in rat plasma by HPLC‐MS/MS
We developed a method for the simultaneous quantification of aceclofenac and its three major metabolites in rat plasma. After protein precipitation with acetonitrile including flufenamic acid as an internal standard (IS), aceclofenac, diclofenac, 4′‐hydroxyaceclofenac, 4′‐hydroxydiclofenac, and the IS were chromatographed on a reverse‐phase C18 analytical column. The isocratic mobile phase of acetonitrile/0.1% formic acid (aq; 9:1 [v/v]) was eluted at 0.3 mL/min. Quantification was performed on a triple‐quadrupole mass spectrometer using electrospray ionization, and the ion transitions were monitored in selective reaction‐monitoring mode. The coefficient of variation in the assay precision was less than 8%, and the accuracy was 92–103%. This method was successfully used to measure the concentrations of aceclofenac and its three major metabolites in rat plasma following the oral administration of a single 20 mg/kg oral dose of aceclofenac.
- Open Access
- 7 June 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 77
Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals
Background: The extended Consolidated Standards of Reporting Trials (CONSORT) Statement for Abstracts was developed to improve the quality of reports of randomized controlled trials (RCTs) because readers often base their assessment of a trial solely on the To date, few data exist regarding whether it has achieved this goal. We evaluated the extent of adherence to the CONSORT for Abstract statement for quality of reports on RCT abstracts by four high-impact general medical journals.Methods: A descriptive analysis of published RCT abstracts in The New England Journal of Medicine (NEJM), The Lancet, The Journal of American Medical Association (JAMA), and the British Medical Journal (BMJ) in the year 2010 was conducted by two reviewers, independently extracting data from a MEDLINE/PubMed search.Results: We identified 271 potential RCT abstracts meeting our inclusion criteria. More than half of the abstracts identified the study as randomized in the title (58.7%; 159/271), reported the specific objective/hypothesis (72.7%; 197/271), described participant eligibility criteria with settings for data collection (60.9%; 165/271), detailed the interventions for both groups (90.8%; 246/271), and clearly defined the primary outcome (94.8%; 257/271). However, the methodological quality domains were inadequately reported: allocation concealment (11.8%; 32/271) and details of blinding (21.0%; 57/271). Reporting the primary outcome results for each group was done in 84.1% (228/271). Almost all of the abstracts reported trial registration (99.3%; 269/271), whereas reports of funding and of harm or side effects from the interventions were found in only 47.6% (129/271) and 42.8% (116/271) of the abstracts, respectively.Conclusions: These findings show inconsistencies and non-adherence to the CONSORT for abstract guidelines, especially in the methodological quality domains. Improvements in the quality of RCT reports can be expected by adhering to existing standards and guidelines as expressed by the CONSORT group.
- 7 June 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 77
Open AccessAssessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals
Background: The extended Consolidated Standards of Reporting Trials (CONSORT) Statement for Abstracts was developed to improve the quality of reports of randomized controlled trials (RCTs) because readers often base their assessment of a trial solely on the To date, few data exist regarding whether it has achieved this goal. We evaluated the extent of adherence to the CONSORT for Abstract statement for quality of reports on RCT abstracts by four high-impact general medical journals.Methods: A descriptive analysis of published RCT abstracts in The New England Journal of Medicine (NEJM), The Lancet, The Journal of American Medical Association (JAMA), and the British Medical Journal (BMJ) in the year 2010 was conducted by two reviewers, independently extracting data from a MEDLINE/PubMed search.Results: We identified 271 potential RCT abstracts meeting our inclusion criteria. More than half of the abstracts identified the study as randomized in the title (58.7%; 159/271), reported the specific objective/hypothesis (72.7%; 197/271), described participant eligibility criteria with settings for data collection (60.9%; 165/271), detailed the interventions for both groups (90.8%; 246/271), and clearly defined the primary outcome (94.8%; 257/271). However, the methodological quality domains were inadequately reported: allocation concealment (11.8%; 32/271) and details of blinding (21.0%; 57/271). Reporting the primary outcome results for each group was done in 84.1% (228/271). Almost all of the abstracts reported trial registration (99.3%; 269/271), whereas reports of funding and of harm or side effects from the interventions were found in only 47.6% (129/271) and 42.8% (116/271) of the abstracts, respectively.Conclusions: These findings show inconsistencies and non-adherence to the CONSORT for abstract guidelines, especially in the methodological quality domains. Improvements in the quality of RCT reports can be expected by adhering to existing standards and guidelines as expressed by the CONSORT group.
- 30 May 2012
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 56 (5) , 797-809
Capsaicin inducesCYP3A4 expression via pregnaneXreceptor andCCAAT/enhancer‐binding proteinβactivation
Scope: Capsaicin (8‐methyl‐N‐vanillyl‐6‐nonenamide) is the principal pungent ingredient in hot red and chili peppers. Many studies have focused on the anticarcinogenic or chemopreventive activities of capsaicin. However, the influence of capsaicin onCYP3A4, its involvement in drug metabolism, and the underlying mechanisms remain unclear.Methods and results: Here, we examined the effect of capsaicin onCYP3A4 expression and the metabolism ofCYP3A1 substrate, nifedipine in maleSprague–Dawley rats. Capsaicin induced the enzymatic activity and expression ofCYP3A4 inHepG2 cells. Treatment with a human pregnaneXreceptor (hPXR) inhibitor reduced the inductive effects of capsaicin onCYP3A4 expression. Capsaicin also induced the activation ofCCAAT/enhancer‐binding proteinβ(C/EBPβ). Moreover, capsaicin increased the activation of the transient receptor potential vanilloid type‐1 receptor downstream signaling componentsCa2+/calmodulin‐dependent protein kinase andAkt. Capsaicin elevated the level ofCYP3A1 in rat liver and significantly increased the biotransformation of nifedipine to dehydronifedipine.Conclusion: From these data, we conclude that capsaicin inducesCYP3A4 expression in vitro and in vivo. This induction was achieved by the activation of hPXRandC/EBPβ. Our results suggest that capsaicin might induceCYP3A4 expression; thus, exposure to capsaicin may increase the metabolism ofCYP3A4 substrate and potentially cause food–drug interactions.
- 30 May 2012
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 56 (5) , 797-809
Capsaicin inducesCYP3A4 expression via pregnaneXreceptor andCCAAT/enhancer‐binding proteinβactivation
Scope: Capsaicin (8‐methyl‐N‐vanillyl‐6‐nonenamide) is the principal pungent ingredient in hot red and chili peppers. Many studies have focused on the anticarcinogenic or chemopreventive activities of capsaicin. However, the influence of capsaicin onCYP3A4, its involvement in drug metabolism, and the underlying mechanisms remain unclear.Methods and results: Here, we examined the effect of capsaicin onCYP3A4 expression and the metabolism ofCYP3A1 substrate, nifedipine in maleSprague–Dawley rats. Capsaicin induced the enzymatic activity and expression ofCYP3A4 inHepG2 cells. Treatment with a human pregnaneXreceptor (hPXR) inhibitor reduced the inductive effects of capsaicin onCYP3A4 expression. Capsaicin also induced the activation ofCCAAT/enhancer‐binding proteinβ(C/EBPβ). Moreover, capsaicin increased the activation of the transient receptor potential vanilloid type‐1 receptor downstream signaling componentsCa2+/calmodulin‐dependent protein kinase andAkt. Capsaicin elevated the level ofCYP3A1 in rat liver and significantly increased the biotransformation of nifedipine to dehydronifedipine.Conclusion: From these data, we conclude that capsaicin inducesCYP3A4 expression in vitro and in vivo. This induction was achieved by the activation of hPXRandC/EBPβ. Our results suggest that capsaicin might induceCYP3A4 expression; thus, exposure to capsaicin may increase the metabolism ofCYP3A4 substrate and potentially cause food–drug interactions.
- 18 January 2012
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (10) , 1133-1136
Simultaneous determination of zolazepam and tiletamine in dog plasma by liquid chromatography coupled to a tandem mass spectrometry
A mixture of tiletamine, a dissociative anesthetic, and zolazepam, a minor tranquilizer, has been widely used as an anesthetic or an immobilizing agent in a variety of animal species. However, interestingly, their pharmacokinetic behaviors have been published only in polar bears and pigs. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for determining the two drugs in dog plasma. After simple protein precipitation with acetonitrile including midazolam (internal standard), the analytes were chromatographed on a reversed‐phase column with a mobile phase of 10 m m ammonium acetate aqueous solution and acetonitrile (1:4, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of zolazepam and tiletamine in plasma after a single intramuscular 10 mg dose of each in beagle dogs. Copyright © 2012 John Wiley & Sons, Ltd.
- 18 January 2012
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (10) , 1133-1136
Simultaneous determination of zolazepam and tiletamine in dog plasma by liquid chromatography coupled to a tandem mass spectrometry
A mixture of tiletamine, a dissociative anesthetic, and zolazepam, a minor tranquilizer, has been widely used as an anesthetic or an immobilizing agent in a variety of animal species. However, interestingly, their pharmacokinetic behaviors have been published only in polar bears and pigs. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for determining the two drugs in dog plasma. After simple protein precipitation with acetonitrile including midazolam (internal standard), the analytes were chromatographed on a reversed‐phase column with a mobile phase of 10 m m ammonium acetate aqueous solution and acetonitrile (1:4, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of zolazepam and tiletamine in plasma after a single intramuscular 10 mg dose of each in beagle dogs. Copyright © 2012 John Wiley & Sons, Ltd.
- 31 December 2011
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 34 (12) , 2073-2078
Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry
Glimepiride, a second-generation sulfonylurea, is a glucose-lowering agent widely used to treat diabetes mellitus. It is converted into metabolite M1 by CYP2C9, and M1 is then transformed into the carboxyl derivative M2 by cytosolic enzymes. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for determining glimepiride, M1, and M2 in human plasma. After simple protein precipitation with acetonitrile, the analytes were chromatographed on a reversed-phase CN column with a mobile phase of 10 mM ammonium acetate aqueous solution and acetonitrile (1:1, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of glimepiride, M1, and M2 in plasma after a single oral 2-mg dose of glimepiride in volunteers.
- 31 December 2011
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 34 (12) , 2073-2078
Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry
Glimepiride, a second-generation sulfonylurea, is a glucose-lowering agent widely used to treat diabetes mellitus. It is converted into metabolite M1 by CYP2C9, and M1 is then transformed into the carboxyl derivative M2 by cytosolic enzymes. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for determining glimepiride, M1, and M2 in human plasma. After simple protein precipitation with acetonitrile, the analytes were chromatographed on a reversed-phase CN column with a mobile phase of 10 mM ammonium acetate aqueous solution and acetonitrile (1:1, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of glimepiride, M1, and M2 in plasma after a single oral 2-mg dose of glimepiride in volunteers.
- 23 August 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (4) , 541-544
Quantitative determination of uridine in rabbit plasma and urine by liquid chromatography coupled to a tandem mass spectrometry
Recently a pyrimidine nucleoside, uridine, has been show to have a protective effect on cultured human corneal epithelial cells, and on dry eye animal model and patients. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry method for the determination of uridine in rabbit plasma and urine. After protein precipitation with methanol including methaqualone (internal standard), the analyte was chromatographed on a reversed‐phase column with a mobile phase of 0.1% formic acid aqueous solution and methanol (1:4, v/v). The accuracy and precision of the assay were in accordance with Food and Drug Administration regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of uridine in plasma and urine after a single oral administration of 450 mg/kg uridine in rabbits. Copyright © 2011 John Wiley & Sons, Ltd.
- 23 August 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (4) , 541-544
Quantitative determination of uridine in rabbit plasma and urine by liquid chromatography coupled to a tandem mass spectrometry
Recently a pyrimidine nucleoside, uridine, has been show to have a protective effect on cultured human corneal epithelial cells, and on dry eye animal model and patients. In this study, we introduce a sensitive liquid chromatography/tandem mass spectrometry method for the determination of uridine in rabbit plasma and urine. After protein precipitation with methanol including methaqualone (internal standard), the analyte was chromatographed on a reversed‐phase column with a mobile phase of 0.1% formic acid aqueous solution and methanol (1:4, v/v). The accuracy and precision of the assay were in accordance with Food and Drug Administration regulations for the validation of bioanalytical methods. This method was used to measure the concentrations of uridine in plasma and urine after a single oral administration of 450 mg/kg uridine in rabbits. Copyright © 2011 John Wiley & Sons, Ltd.